Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy.
The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab
Over the past several months, my conversations with colleagues in the Alzheimer’s field have featured an unusual sentiment: optimism inflected with worry. Optimism because, after
June 16, 2023